Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.45 USD | -11.04% | -37.54% | -86.96% |
May. 16 | Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding | CI |
May. 14 | Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance | MT |
Financials (USD)
Sales 2022 | - | Sales 2023 | 2.2 | Capitalization | 13.61M |
---|---|---|---|---|---|
Net income 2022 | -73M | Net income 2023 | -37M | EV / Sales 2022 | - |
Net Debt 2022 | 4.59M | Net Debt 2023 | 11.23M | EV / Sales 2023 | 11,278,476 x |
P/E ratio 2022 |
-0.98
x | P/E ratio 2023 |
-0.18
x | Employees | 16 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.42% |
Latest transcript on Seelos Therapeutics, Inc.
1 day | -12.88% | ||
1 week | -38.84% | ||
Current month | -36.38% | ||
1 month | -45.50% | ||
3 months | -78.56% | ||
6 months | -96.52% | ||
Current year | -87.23% |
Managers | Title | Age | Since |
---|---|---|---|
Raj Mehra
CEO | Chief Executive Officer | 64 | 86-12-31 |
Director of Finance/CFO | 52 | 18-12-31 | |
Karen Fusaro
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 77 | 21-08-31 | |
Richard Pascoe
CHM | Chairman | 60 | 13-02-28 |
Daniel O'Connor
BRD | Director/Board Member | 59 | 18-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-22 | 1.45 | -11.04% | 177 755 |
24-05-21 | 1.63 | -6.59% | 112,568 |
24-05-20 | 1.745 | -8.16% | 134,915 |
24-05-17 | 1.9 | -18.80% | 234,265 |
24-05-16 | 2.34 | +0.79% | 202,459 |
Delayed Quote Nasdaq, May 22, 2024 at 11:26 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-87.23% | 2.79M | |
+9.83% | 114B | |
+12.97% | 107B | |
-4.69% | 22.22B | |
-0.67% | 21.28B | |
-4.64% | 18.8B | |
-6.23% | 17.51B | |
-39.36% | 17.17B | |
+5.93% | 14.14B | |
+34.48% | 12.2B |
- Stock Market
- Equities
- SEEL Stock